Aytu BioPharma (NASDAQ:AYTU) Posts Quarterly Earnings Results, Misses Expectations By $0.37 EPS

Aytu BioPharma (NASDAQ:AYTU) posted its earnings results on Thursday. The company reported ($0.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.37), Zacks reports. The business had revenue of $17.98 million during the quarter. Aytu BioPharma had a negative return on equity of 31.31% and a negative net margin of 14.60%.

Aytu BioPharma Stock Down 17.2 %

AYTU stock opened at $2.36 on Friday. The firm has a market capitalization of $14.09 million, a PE ratio of -0.90 and a beta of -1.43. Aytu BioPharma has a twelve month low of $1.87 and a twelve month high of $3.50. The stock’s 50 day moving average is $2.53 and its 200-day moving average is $2.83.

Aytu BioPharma Company Profile

Aytu Biopharma, Inc, a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old.